porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2016113-14porozendo-8931Research ArticleСтатьиArticlesWNT СИГНАЛЬНЫЙ ПУТЬ В ИССЛЕДОВАНИЯХ КОСТНОЙ ТКАНИWNT-SIGNALING PATHWAY IN THE BONE TISSUE STUDIESБелаяЖ ЕBelayaZh E
зав. отделением нейроэндокринологии и остеопатий, д.м.н
janna.belaya@gmail.comФГБУ «Эндокринологический научный центр» Минздрава России201615122016191№1 (2016)1314Copyright © Белая Ж.Е., 20162016Белая Ж.Е.Belaya Z.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/8931ReferencesNusse R, Varmus H. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 1982, 31, 99-109Nusse R, Varmus H. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 1982, 31, 99-109Nüsslein-Volhard C, Wieschaus E (October 1980). «Mutations affecting segment number and polarity in Drosophila». Nature 287 (5785): 795-801. DOI:10.1038/287795a0. PMID 6776413.Nüsslein-Volhard C, Wieschaus E (October 1980). «Mutations affecting segment number and polarity in Drosophila». Nature 287 (5785): 795-801. DOI:10.1038/287795a0. PMID 6776413.Holstein TW. The evolution of the Wnt pathway. Cold Spring Harb Perspect Biol 2012, 4: a007922Holstein TW. The evolution of the Wnt pathway. Cold Spring Harb Perspect Biol 2012, 4: a007922Clevers H, Nusse R.: Wnt/β-Catenin signaling and disease. Cell, 2012, 149, 1192-1205Clevers H, Nusse R.: Wnt/β-Catenin signaling and disease. Cell, 2012, 149, 1192-1205Willert K, Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol, 2012, 4:a007864Willert K, Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol, 2012, 4:a007864Wang Y, Li Y, Paulson C, Shao J-Z, Zhang X, Wu M, Chen.: Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci, 2014, 19, 379-407Wang Y, Li Y, Paulson C, Shao J-Z, Zhang X, Wu M, Chen.: Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci, 2014, 19, 379-407Гребенникова ТА, Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА, Дедов ИИ: Эпигенетические аспекты остеопороза. Вестник Российской Академии Медицинских Наук, 2015, Том 70, №5, стр. 541-548Гребенникова ТА, Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА, Дедов ИИ: Эпигенетические аспекты остеопороза. Вестник Российской Академии Медицинских Наук, 2015, Том 70, №5, стр. 541-548Yavropoulou MP, Xygonakis C, Lolou M, Karadimou F, Yovos JG.: The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis. Hormones, 2014, 13, 476-487Yavropoulou MP, Xygonakis C, Lolou M, Karadimou F, Yovos JG.: The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis. Hormones, 2014, 13, 476-487Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II.: Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. J. Osteoporosis International, 2013, Vol. 24, pp. 2191-2199 (DOI: 10.1007/s00198-013-2268-y)Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II.: Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. J. Osteoporosis International, 2013, Vol. 24, pp. 2191-2199 (DOI: 10.1007/s00198-013-2268-y)Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis. Arthritis Rheum 58: 1674-1686Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis. Arthritis Rheum 58: 1674-1686Larsson S. Anti-sclerostin - is there an indication? Injury. 2016;47(1):31-35. doi: 10.1016/S0020-1383(16)30008-0Larsson S. Anti-sclerostin - is there an indication? Injury. 2016;47(1):31-35. doi: 10.1016/S0020-1383(16)30008-0McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
The authors declare that there are no conflicts of interest present.